蛋白酶体抑制剂耐药性多发性骨髓瘤的研究进展。
Research progress in proteasome inhibitor resistance to multiple myeloma.
机构信息
Department of Hematology, Loudi Gereral Hospital, Loudi Hunan 417000.
Department of Hematology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
出版信息
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Aug 28;46(8):900-908. doi: 10.11817/j.issn.1672-7347.2021.200430.
Abstract
Multiple myeloma (MM) is a highly heterogeneous malignant plasma cell disease. Proteasome inhibitors (PIs) are the first line of medicine for MM. Bortezomib, ixazomib, and carfilzomib are also widely used for MM. Marizomib, oprozomib, and KZR-616 are in clinical trials. However, the drug resistance of PIs in MM is still a problem. The mechanisms for PIs resistance to MM include ubiquitin-proteasome pathway, autophagy lysosome pathway, endoplasmic reticulum stress pathway, cell survival signal pathway, exosome-mediated resistance, and bone marrow microenvironment-mediated resistance.
摘要
多发性骨髓瘤（MM）是一种高度异质性的恶性浆细胞疾病。蛋白酶体抑制剂（PIs）是 MM 的一线药物。硼替佐米、伊沙佐米和卡非佐米也广泛用于 MM。马拉佐米、奥普佐米和 KZR-616 正在临床试验中。然而，PI 在 MM 中的耐药性仍然是一个问题。PI 对 MM 耐药的机制包括泛素-蛋白酶体途径、自噬溶酶体途径、内质网应激途径、细胞存活信号途径、外泌体介导的耐药性和骨髓微环境介导的耐药性。
相似文献
1
Research progress in proteasome inhibitor resistance to multiple myeloma.蛋白酶体抑制剂耐药性多发性骨髓瘤的研究进展。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Aug 28;46(8):900-908. doi: 10.11817/j.issn.1672-7347.2021.200430.
2
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.基于环氧酮的蛋白酶体抑制剂卡非佐米和口服生物利用度的奥普佐米除了具有抗骨髓瘤作用外，还具有抗吸收和促进骨形成的活性。
Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.
3
The effects of proteasome inhibitors on bone remodeling in multiple myeloma.蛋白酶体抑制剂对多发性骨髓瘤骨重塑的影响。
Bone. 2016 May;86:131-8. doi: 10.1016/j.bone.2016.02.019. Epub 2016 Mar 3.
4
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.蛋白酶体抑制与免疫疗法联合应用：多发性骨髓瘤的最新进展
Blood Rev. 2023 Sep;61:101100. doi: 10.1016/j.blre.2023.101100. Epub 2023 May 27.
5
Safety of proteasome inhibitors for treatment of multiple myeloma.蛋白酶体抑制剂治疗多发性骨髓瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):167-183. doi: 10.1080/14740338.2017.1259310. Epub 2016 Nov 28.
6
[Proteasome inhibitors in treatment of multiple myeloma].蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用
Klin Onkol. 2013;26(1):11-8. doi: 10.14735/amko201311.
7
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.克服蛋白酶体抑制剂耐药性的不同策略——引入 20 年后的总结。
Int J Mol Sci. 2024 Aug 16;25(16):8949. doi: 10.3390/ijms25168949.
8
[Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].新型蛋白酶体抑制剂在复发/难治性多发性骨髓瘤治疗中的作用
Rinsho Ketsueki. 2018;59(10):2162-2168. doi: 10.11406/rinketsu.59.2162.
9
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.蛋白酶体抑制剂——多发性骨髓瘤的分子基础及当前研究进展
J Cell Mol Med. 2014 Jun;18(6):947-61. doi: 10.1111/jcmm.12279. Epub 2014 Apr 8.
10
Second Generation Proteasome Inhibitors in Multiple Myeloma.第二代蛋白酶体抑制剂在多发性骨髓瘤中的应用
Anticancer Agents Med Chem. 2017;17(7):920-926. doi: 10.2174/1871520616666160902101622.
引用本文的文献
1
The role of proteasomes in tumorigenesis.蛋白酶体在肿瘤发生中的作用。
Genes Dis. 2023 Aug 6;11(4):101070. doi: 10.1016/j.gendis.2023.06.037. eCollection 2024 Jul.
2
Drug Resistance: The Role of Exosomal miRNA in the Microenvironment of Hematopoietic Tumors.耐药性：外泌体 miRNA 在造血肿瘤微环境中的作用。
Molecules. 2022 Dec 23;28(1):116. doi: 10.3390/molecules28010116.
本文引用的文献
1
Roles of noncoding RNAs in drug resistance in multiple myeloma.非编码 RNA 在多发性骨髓瘤耐药中的作用。
J Cell Physiol. 2020 Nov;235(11):7681-7695. doi: 10.1002/jcp.29726. Epub 2020 Apr 23.
2
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.蛋白酶体抑制剂耐药性：多发性骨髓瘤和套细胞淋巴瘤的经验教训。
Adv Exp Med Biol. 2020;1233:153-174. doi: 10.1007/978-3-030-38266-7_6.
3
Integrins in multiple myeloma.多发性骨髓瘤中的整合素
Inflamm Regen. 2020 Mar 30;40:4. doi: 10.1186/s41232-020-00113-y. eCollection 2020.
4
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.基于伊沙佐米的方案治疗复发/难治性多发性骨髓瘤：真实世界数据与临床试验结果是否一致？一项多中心以色列登记研究。
Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20.
5
Runt-related transcription factor 2 influences cell adhesion-mediated drug resistance and cell proliferation in B-cell non-Hodgkin's lymphoma and multiple myeloma.与Runt相关的转录因子2影响B细胞非霍奇金淋巴瘤和多发性骨髓瘤中细胞黏附介导的耐药性及细胞增殖。
Leuk Res. 2020 May;92:106340. doi: 10.1016/j.leukres.2020.106340. Epub 2020 Mar 9.
6
Exploring the proteasome system: A novel concept of proteasome inhibition and regulation.探索蛋白酶体系统：蛋白酶体抑制和调节的新概念。
Pharmacol Ther. 2020 Jul;211:107526. doi: 10.1016/j.pharmthera.2020.107526. Epub 2020 Mar 13.
7
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.硼替佐米巩固或维持治疗在免疫化疗和自体干细胞移植治疗套细胞淋巴瘤中的应用：CALGB/Alliance 50403 研究。
Am J Hematol. 2020 Jun;95(6):583-593. doi: 10.1002/ajh.25783. Epub 2020 Apr 6.
8
Bortezomib for autoimmune hemolytic anemia after intestinal transplantation.硼替佐米治疗肠移植后自身免疫性溶血性贫血。
Pediatr Transplant. 2020 Jun;24(4):e13700. doi: 10.1111/petr.13700. Epub 2020 Mar 12.
9
Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells.硼替佐米和表柔比星对结直肠癌细胞中 Fas 的调控。
J Chemother. 2020 Jul;32(4):193-201. doi: 10.1080/1120009X.2020.1740389. Epub 2020 Mar 12.
10
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.硼替佐米为基础的巩固或维持治疗多发性骨髓瘤的Meta 分析。
Blood Cancer J. 2020 Mar 6;10(3):33. doi: 10.1038/s41408-020-0298-1.
Zotero 插件